Devert-50/Devert-100 Use In Pregnancy & Lactation

The safety of desvenlafaxine in pregnancy in humans has not been established. Desvenlafaxine should only be administered to pregnant women if the expected benefits outweigh the possible risks. If desvenlafaxine is used until or shortly before birth, discontinuation effects in the newborn should be considered. Complications, including the need for respiratory support, tube feeding or prolonged hospitalization have been reported in neonates exposed to SNRIs or SSRIs late in the third-quarter. Such complications can arise immediately upon delivery. Exposure to SNRIs in mid to late pregnancy may increase the risk of preeclampsia, and exposure to SNRIs near delivery may increase the risk for postpartum hemorrhage.
Desvenlafaxine is a drug classified in category C of pregnancy risk. Therefore, this medicine should not be used by pregnant women without medical or dentist surgeon guidance.
Desvenlafaxine (O-desmethylvenlafaxine) is excreted in the human milk. Because of the potential for serious adverse reactions in infants due to exposure to desvenlafaxine, it must decide to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Administer desvenlafaxine to breastfeeding women only if the expected benefits outweigh the possible risks.